Patents by Inventor Christa C. Chrovian

Christa C. Chrovian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P2X7 MODULATORS
    Publication number: 20240116930
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 11, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus ALCAZAR VACA, Jose Lgnacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • P2X7 modulators
    Patent number: 11820770
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: November 21, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20230338341
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: June 29, 2023
    Publication date: October 26, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
    Patent number: 11759455
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: September 19, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20230000833
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: September 14, 2021
    Publication date: January 5, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • P2X7 MODULATORS
    Publication number: 20220235062
    Abstract: The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Application
    Filed: February 7, 2022
    Publication date: July 28, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Jose Ignacio ANDRES GIL, Christa C. CHROVIAN, Michael A. LETAVIC, Jason C. RECH, Dale A. RUDOLPH, Akinola SOYODE-JOHNSON
  • P2X7 MODULATORS
    Publication number: 20220213095
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 7, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus ALCAZAR VACA, Jose Ignacio ANDRES GIL, Christa C. CHROVIAN, Heather R. COATE, Meri DE ANGELIS, Curt A. DVORAK, Christine F. GELIN, Michael A. LETAVIC, Brad M. SAVALL, Akinola SOYODE-JOHNSON, Brice M. STENNE, Devin M. SWANSON
  • P2X7 modulators
    Patent number: 11225478
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 18, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
    Patent number: 11207298
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: December 28, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20210069155
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: March 3, 2020
    Publication date: March 11, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • P2X7 Modulators
    Publication number: 20200325138
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Patent number: 10766880
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: September 8, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • P2X7 modulators
    Patent number: 10703749
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: July 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators
    Patent number: 10617676
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: April 14, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C Chrovian, Michael A Letavic, Jason C Rech, Dale A Rudolph, Akinola Soyode-Johnson, Brice M Stenne, Jessica L Wall
  • Substituted 4-azaindoles and their use as GluN2B receptor modulators
    Patent number: 10377753
    Abstract: Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 13, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Jessica L. Wall
  • SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
    Publication number: 20190135791
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: December 31, 2018
    Publication date: May 9, 2019
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • P2X7 Modulators
    Publication number: 20190092770
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 28, 2019
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Patent number: 10233173
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 19, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • P2X7 modulators
    Patent number: 10150765
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: December 11, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
    Publication number: 20180334451
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: July 26, 2018
    Publication date: November 22, 2018
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang